Zoetis Inc. (NYSE:ZTS) Shares Acquired by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 15.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,453 shares of the company’s stock after acquiring an additional 9,451 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Zoetis were worth $14,155,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Darwin Wealth Management LLC acquired a new stake in Zoetis during the 3rd quarter worth about $31,000. First Personal Financial Services acquired a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the third quarter worth approximately $33,000. Quarry LP increased its holdings in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. Finally, Fortitude Family Office LLC increased its holdings in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after buying an additional 222 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus increased their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Zoetis has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Price Performance

Zoetis stock opened at $176.96 on Monday. The business’s 50-day simple moving average is $185.62 and its 200 day simple moving average is $180.72. The stock has a market cap of $79.84 billion, a price-to-earnings ratio of 33.26, a P/E/G ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the business posted $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is presently 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.